Phoenix, AZ— bioSyntagma, LLC, a precision medicine company, has been awarded a nearly $200,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop a new platform for mapping multi-omic biomarkers from single-cells in cancer patient biopsies. bioSyntagma’s Principal Scientist, Dmitry Derkach, M.D., […]
In the News
About this project
Join us in making cancer research faster and more informative. bioSyntagma has developed a device that enables researchers and drug developers to get closer to making personalized medicine a reality by studying drug resistance in cancer patients.